Electronic Medical Record–Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non–Small Cell Lung Cancer: Results From a Prospective Clinical Trial

Melina E. Marmarelis,Dylan G. Scholes,Tara L. McWilliams,Wei-Ting Hwang,John Kosteva,Michael R. Costello,Lova Sun,Aditi P. Singh,Kelsey S. Lau-Min,Abigail Doucette,Peter E. Gabriel,Anthony O. Martella,Megan A. Roy,Jeffrey C. Thompson,Roger B. Cohen,David W. Dougherty,Lawrence N. Shulman,Corey J. Langer,Justin E. Bekelman,Erica L. Carpenter,Charu Aggarwal
DOI: https://doi.org/10.1200/op.24.00070
2024-07-03
JCO Oncology Practice
Abstract:PURPOSE Less than half of the patients with newly diagnosed metastatic non–small cell lung cancer (NSCLC) undergo comprehensive molecular testing. We designed an electronic medical record (EMR)–based “nudge intervention” to prompt plasma-based molecular testing at the time of initial medical oncology consultation. METHODS A nonrandomized prospective trial was conducted at the University of Pennsylvania's academic practice and two affiliated community practices. Molecular genotyping was performed by tissue- and/or plasma-based next generation sequencing methods. Comprehensive testing was defined as testing for EGFR, ALK, BRAF, ROS1, MET, RET, KRAS, and NTRK. Guideline-concordant treatment was defined as the use of the appropriate first-line (1L) therapy as per the National Comprehensive Cancer Network (NCCN) guidelines. Proportion of patients with comprehensive molecular genotyping results available at any time, molecular results available before 1L therapy, and guideline-concordant 1L treatment were compared between the preintervention and postintervention cohorts using Fisher's exact test or Pearson's chi-squared test. RESULTS Five hundred and thirty-three patients were included, 376 in the preintervention cohort and 157 in the postintervention cohort. After implementation of the EMR-based nudge, a higher proportion of patients underwent comprehensive molecular testing in the postintervention versus the preintervention cohort (100% v 88%, P = <.001), had results of comprehensive molecular testing available before initiating 1L treatment (97.3% v 91.6%, P = .026), and received NCCN guideline-concordant care (89.8% v 78.2%, P = .035). CONCLUSION Across three practice sites in a large health system, implementation of a provider team–focused EMR-based nudge intervention was feasible, and led to a higher number of patients with NSCLC undergoing comprehensive molecular genotyping. These findings demonstrate that behavioral nudges can promote molecular testing and should be studied further as a tool to improve guideline-concordant care in both community and academic sites.
oncology
What problem does this paper attempt to address?